Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma

被引：1
|
作者：
Fu Ruiying [1 ]
Liang Yuanzheng [1 ]
Wei Liqiang [1 ]
Liu Xindi [1 ]
Piao Yingshi [6 ]
Wang Liang [1 ]
机构：
[1] Department of Hematology
[2] Beijing Tongren Hospital  3. Capital Medical University  4. Beijing 100730  5. China
[3] Department of Pathology
来源：
中华医学杂志英文版 | 2023年 / 136卷 / 06期
基金：
中国国家自然科学基金; 北京市自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R733.1 [网状内皮系统肿瘤];
学科分类号：
100214 ;
摘要：
<正>
引用
收藏
相关论文
共 50 条
  • [1] Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma
    Fu, Ruiying
    Liang, Yuanzheng
    Wei, Liqiang
    Liu, Xindi
    Piao, Yingshi
    Wang, Liang
    CHINESE MEDICAL JOURNAL, 2023, 136 (06) : 732 - 734
  • [2] The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
    Zhang, Lei
    Li, Sucai
    Jia, Sisi
    Nan, Feifei
    Li, Zhaoming
    Cao, Jingyu
    Fan, Shanshan
    Zhang, Chao
    Su, Liping
    Wang, Jinghua
    Xue, Hongwei
    Zhang, Mingzhi
    ONCOTARGET, 2016, 7 (36) : 58396 - 58404
  • [3] Efficacy of gemcitabine, pegaspargase, cisplatin and dexamethasone (DDGP) in the advanced stage extranodal NK/T-cell lymphoma, and its correlation with epstein-barr virus transformation
    Zhao, Q.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 464 - 465
  • [4] Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients
    Zhiyuan Zhou
    Xiang Li
    Changying Chen
    Xin Li
    Lei Zhang
    Ling Li
    Xinhua Wang
    Wang Ma
    Xiaorui Fu
    Jingjing Wu
    Zhenchang Sun
    Xudong Zhang
    Zhaoming Li
    Jiaqin Yan
    Yu Chang
    Lisha Lu
    Beibei Qin
    Xiaoli Li
    Jianguo Wen
    Mingzhi Zhang
    Annals of Hematology, 2014, 93 : 1889 - 1894
  • [5] Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients
    Zhou, Zhiyuan
    Li, Xiang
    Chen, Changying
    Li, Xin
    Zhang, Lei
    Li, Ling
    Wang, Xinhua
    Ma, Wang
    Fu, Xiaorui
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Li, Zhaoming
    Yan, Jiaqin
    Chang, Yu
    Lu, Lisha
    Qin, Beibei
    Li, Xiaoli
    Wen, Jianguo
    Zhang, Mingzhi
    ANNALS OF HEMATOLOGY, 2014, 93 (11) : 1889 - 1894
  • [6] Treatment of extranodal NK and T-cell lymphoma
    Suzuki, Ritsuro
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 11 - 11
  • [7] New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma
    Yi, Wu
    Yang, Tianxin
    Lin, Sisi
    Hao, Rui
    Yu, Jin
    Wang, Ying
    Tong, Xiangming
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 401 - 407
  • [8] Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study
    Liu, Tao
    Zhu, Fang
    Xiao, Yin
    Li, Qiuhui
    Liu, Xinxiu
    Yang, Kunyu
    Wu, Gang
    Zhang, Liling
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 5061 - 5069
  • [9] SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type
    Wei, Liqiang
    Wang, Liang
    Cong, Jia
    Yang, Lei
    Ye, Jin
    Li, Xin
    Yao, Na
    Yang, Jing
    Wang, Jingwen
    LEUKEMIA RESEARCH, 2020, 96
  • [10] Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus
    Zhao, Qian
    Fan, Shanshan
    Chang, Yu
    Liu, Xiyang
    Li, Wencai
    Ma, Qianwen
    Li, Yang
    Wang, Yan
    Zhang, Lei
    Zhang, Mingzhi
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 3555 - 3564
12345